Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
0(0%)
Results Posted
75%(9 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_2
4
25%
Ph phase_4
3
19%
Ph phase_3
4
25%
Ph phase_1
2
13%
Ph early_phase_1
1
6%
Ph not_applicable
1
6%

Phase Distribution

3

Early Stage

4

Mid Stage

7

Late Stage

Phase Distribution15 total trials
Early Phase 1First-in-human
1(6.7%)
Phase 1Safety & dosage
2(13.3%)
Phase 2Efficacy & side effects
4(26.7%)
Phase 3Large-scale testing
4(26.7%)
Phase 4Post-market surveillance
3(20.0%)
N/ANon-phased studies
1(6.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

12 of 14 finished

Non-Completion Rate

14.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(12)
Terminated(2)
Other(2)

Detailed Status

Completed12
unknown2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
92.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (6.7%)
Phase 12 (13.3%)
Phase 24 (26.7%)
Phase 34 (26.7%)
Phase 43 (20.0%)
N/A1 (6.7%)

Trials by Status

withdrawn16%
completed1275%
terminated16%
unknown213%

Recent Activity

0 active trials
Showing 5 of 16
completedphase_1

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
completedphase_2

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
terminatedphase_2

Intranasal Ketorolac Trial

NCT06083571
completedphase_3

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

NCT03367572
completedphase_2

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

NCT00001337
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT02858310Phase 1

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Completed
NCT01391962Phase 2

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Completed
NCT06083571Phase 2

Intranasal Ketorolac Trial

Terminated
NCT03367572Phase 3

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Completed
NCT00001337Phase 2

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Completed
NCT01851369Phase 1

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

Completed
NCT05013437Early Phase 1

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

Withdrawn
NCT06182098Not Applicable

Intravenous Fluids in Pediatric Migraine

Unknown
NCT02600741

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed
NCT02389829Phase 4

Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine

Completed
NCT00364806Phase 4

Prochlorperazine vs Metoclopramide

Completed
NCT02779959Phase 3

Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT

Unknown
NCT02657031Phase 4

The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine

Completed
NCT00475085Phase 3

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Completed
NCT00020657Phase 3

Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

Completed
NCT00590317Phase 2

Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department

Completed

All 16 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
16